Alvameline Tartrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529021

CAS#: 159792-14-0 (Alvameline Tartrate)

Description: Alvameline Tartrate is a muscarinic M1 receptor agonist and M2/M3 receptor antagonist potentially for treatment of urinary incontinence.


Chemical Structure

img
Alvameline Tartrate
CAS# 159792-14-0 (Alvameline Tartrate)

Theoretical Analysis

MedKoo Cat#: 529021
Name: Alvameline Tartrate
CAS#: 159792-14-0 (Alvameline Tartrate)
Chemical Formula: C13H21N5O6
Exact Mass:
Molecular Weight: 343.34
Elemental Analysis: C, 45.48; H, 6.17; N, 20.40; O, 27.96

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 120241-31-8 (Alvameline free base)  

Synonym: LU-25-109T; LU-25109T; LU 25 109T; LU 25109T

IUPAC/Chemical Name: 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine (2R,3R)-2,3-dihydroxysuccinate

InChi Key: JHGFYOXAUPXDGA-LREBCSMRSA-N

InChi Code: InChI=1S/C9H15N5.C4H6O6/c1-3-14-11-9(10-12-14)8-5-4-6-13(2)7-8;5-1(3(7)8)2(6)4(9)10/h5H,3-4,6-7H2,1-2H3;1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1

SMILES Code: CN1CC(C2=NN(CC)N=N2)=CCC1.O=C(O)[C@H](O)[C@@H](O)C(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 343.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Waldeck K, Larsson B, Sandberg B, Andersson K-. Actions of the new antimuscarinic compound Lu 25-109 on isolated human and pig detrusor. Neurourol Urodyn. 2002;21(1):92-8. PubMed PMID: 11835429.

2: Sveigaard HH, Dalgaard L. Evaluation of blood-brain barrier passage of a muscarine M1 agonist and a series of analogous tetrahydropyridines measured by in vivo microdialysis. Pharm Res. 2000 Jan;17(1):70-6. PubMed PMID: 10714611.

3: Forlenza OV, Spink JM, Dayanandan R, Anderton BH, Olesen OF, Lovestone S. Muscarinic agonists reduce tau phosphorylation in non-neuronal cells via GSK-3beta inhibition and in neurons. J Neural Transm (Vienna). 2000;107(10):1201-12. PubMed PMID: 11129110.

4: Thal LJ, Forrest M, Loft H, Mengel H. Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer's disease. Lu25-109 Study Group. Neurology. 2000 Jan 25;54(2):421-6. PubMed PMID: 10668706.

5: Christensen EB, Andersen JB, Pedersen H, Jensen KG, Dalgaard L. Metabolites of [(14)C]-5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3, 6-tetrahydropyridine in mice, rats, dogs, and humans. Drug Metab Dispos. 1999 Nov;27(11):1341-9. PubMed PMID: 10534320.

6: Jensen KG, Dalgaard L. In vitro metabolism of the M1-muscarinic agonist 5-(2-ethyl-2H-tetrazol-5-yl)-1-methyl-1,2,3,6-tetrahydropyridine by human hepatic cytochromes P-450 determined at pH 7.4 and 8.5. Drug Metab Dispos. 1999 Jan;27(1):125-32. PubMed PMID: 9884321.

7: Sánchez C, Arnt J, Didriksen M, Dragsted N, Moltzen Lenz S, Matz J. In vivo muscarinic cholinergic mediated effects of Lu 25-109, a M1 agonist and M2/M3 antagonist in vitro. Psychopharmacology (Berl). 1998 Jun;137(3):233-40. PubMed PMID: 9683000.

8: Bymaster FP, Carter PA, Peters SC, Zhang W, Ward JS, Mitch CH, Calligaro DO, Whitesitt CA, DeLapp N, Shannon HE, Rimvall K, Jeppesen L, Sheardown MJ, Fink-Jensen A, Sauerberg P. Xanomeline compared to other muscarinic agents on stimulation of phosphoinositide hydrolysis in vivo and other cholinomimetic effects. Brain Res. 1998 Jun 8;795(1-2):179-90. PubMed PMID: 9622623.

9: Müller D, Wiegmann H, Langer U, Moltzen-Lenz S, Nitsch RM. Lu 25-109, a combined m1 agonist and m2 antagonist, modulates regulated processing of the amyloid precursor protein of Alzheimer's disease. J Neural Transm (Vienna). 1998;105(8-9):1029-43. PubMed PMID: 9869334.

10: Sramek JJ, Forrest M, Mengel H, Jhee SS, Hourani J, Cutler NR. A bridging study of LU 25-109 in patients with probable Alzheimer's disease. Life Sci. 1998;62(3):195-202. PubMed PMID: 9488097.

11: Pike BR, Hamm RJ. Activating the posttraumatic cholinergic system for the treatment of cognitive impairment following traumatic brain injury. Pharmacol Biochem Behav. 1997 Aug;57(4):785-91. PubMed PMID: 9259007.

12: Pike BR, Hamm RJ. Chronic administration of a partial muscarinic M1 receptor agonist attenuates decreases in forebrain choline acetyltransferase immunoreactivity following experimental brain trauma. Exp Neurol. 1997 Sep;147(1):55-65. PubMed PMID: 9294403.